(-0.06%) 5 304.68 points
(0.10%) 39 845 points
(-0.35%) 16 736 points
(-1.00%) $79.00
(-2.22%) $2.69
(-0.19%) $2 433.90
(-0.51%) $32.26
(0.03%) $1 064.00
(0.10%) $0.922
(-0.35%) $10.66
(-0.04%) $0.787
(-0.61%) $90.12
Live Chart Being Loaded With Signals
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States...
Stats | |
---|---|
本日の出来高 | 2 144.00 |
平均出来高 | 3.85M |
時価総額 | 10.38M |
EPS | $0 ( 2024-05-09 ) |
次の収益日 | ( $-0.0900 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.140 |
ATR14 | $0.00400 (0.67%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Cittadine Andrew | Sell | 8 952 | Restricted Stock Units |
2024-03-31 | Cittadine Andrew | Buy | 8 952 | Common Stock |
2024-03-31 | Cittadine Andrew | Sell | 3 098 | Common Stock |
2024-03-31 | Tsuchimoto Kim R | Sell | 9 956 | Restricted Stock Units |
2024-03-31 | Tsuchimoto Kim R | Buy | 9 956 | Common Stock |
INSIDER POWER |
---|
36.17 |
Last 100 transactions |
Buy: 1 127 208 | Sell: 341 037 |
ボリューム 相関
Monopar Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
BLKB | -0.804 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Monopar Therapeutics Inc 相関 - 通貨/商品
Monopar Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-0.610 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-0.610 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-0.830 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.730 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。